Research Analysts Offer Predictions for ONCY Q3 Earnings

Oncolytics Biotech Inc. (NASDAQ:ONCY) – Research analysts at HC Wainwright decreased their Q3 2025 EPS estimates for shares of Oncolytics Biotech in a research note issued on Tuesday, September 16th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($0.12) for the quarter, down from their prior estimate of ($0.11). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s FY2025 earnings at ($0.28) EPS.

Oncolytics Biotech (NASDAQ:ONCY) last posted its quarterly earnings results on Friday, August 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.06.

ONCY has been the topic of several other reports. Lake Street Capital initiated coverage on shares of Oncolytics Biotech in a research report on Wednesday, August 13th. They issued a “buy” rating and a $7.00 price objective on the stock. Wall Street Zen upgraded shares of Oncolytics Biotech from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $5.00.

Oncolytics Biotech Stock Performance

Oncolytics Biotech stock opened at $1.36 on Thursday. The firm’s 50-day moving average is $1.10 and its 200-day moving average is $0.77. Oncolytics Biotech has a 1 year low of $0.33 and a 1 year high of $1.53. The company has a market cap of $136.49 million, a P/E ratio of -5.04 and a beta of 1.19.

Institutional Trading of Oncolytics Biotech

A hedge fund recently raised its stake in Oncolytics Biotech stock. Seeds Investor LLC lifted its position in Oncolytics Biotech Inc. (NASDAQ:ONCY) by 17.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 223,767 shares of the company’s stock after acquiring an additional 33,826 shares during the period. Seeds Investor LLC owned about 0.23% of Oncolytics Biotech worth $173,000 as of its most recent SEC filing. 6.82% of the stock is currently owned by institutional investors and hedge funds.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.